Market Overview

I think you’ll love what you hear,
what you’ll see and the opportunities
that will be set before you.
- Jon Najarian

Sabra's Texas Exits Removes A Year-Long Overhang


Canaccord's Paul Morgan reiterated Sabra Health Care REIT (NASDAQ: SBRA)'s Hold rating with a price target of $23.

Sabra announced Tuesday it will sell its Forest Park Dallas, which Morgan praised. "Sabra has been working on realizing its "Texit" for months, and today's announcement that the sale of Forest Park Medical Center Dallas is a welcome positive," stated the analyst. This will mark a "full exit" from Sabra's struggling Texas hospital investments by midyear.

The Canaccord analyst is happy to see the company shifting its focus on the Sabra's "$200 million senior housing acquisition pipeline."

Due to the beneficial shift, the analyst raised 2017 EBITDA estimates from $225.0 million to $227.10 million.

Latest Ratings for SBRA

Feb 2019DowngradesMarket PerformUnderperform
Dec 2018MaintainsMarket PerformMarket Perform
Nov 2018DowngradesNeutralUnderperform

View More Analyst Ratings for SBRA
View the Latest Analyst Ratings

Posted-In: Canaccord Paul MorganAnalyst Color Reiteration Analyst Ratings


Related Articles (SBRA)

View Comments and Join the Discussion!

Latest Ratings

View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at

EnerSys Q4'16 Earnings Conference Call: Full Transcript

Cushing Inventories Decline, Anchored Ships Holding Crude Oil Sent Out To Sea